Loading...
Loading...
Found 8 Skills
Access ClinPGx pharmacogenomics data (successor to PharmGKB). Query gene-drug interactions, CPIC guidelines, allele functions, for precision medicine and genotype-guided dosing decisions.
Generates comprehensive drug research reports with compound disambiguation, evidence grading, and mandatory completeness sections. Covers identity, chemistry, pharmacology, targets, clinical trials, safety, pharmacogenomics, and ADMET properties. Use when users ask about drugs, medications, therapeutics, or need drug profiling, safety assessment, or clinical development research.
Search and retrieve clinical practice guidelines across 12+ authoritative sources including NICE, WHO, ADA, AHA/ACC, NCCN, SIGN, CPIC, CMA, CTFPHC, GIN, MAGICapp, PubMed, EuropePMC, TRIP, and OpenAlex. Covers disease management, cardiology, oncology, diabetes, pharmacogenomics, and more. Use when users ask about clinical guidelines, treatment recommendations, standard of care, evidence-based medicine, or drug-gene dosing recommendations.
Guide pharmacogenomics (PGx) research -- drug-gene interaction lookup, CPIC guideline retrieval, variant-drug annotation, allele function status, FDA biomarker labeling, and clinical dosing recommendations. Covers the full CPIC-to-PharmGKB-to-clinical-recommendation workflow. Use when users ask about pharmacogenomics, drug-gene interactions, CPIC guidelines, genotype-guided dosing, PGx biomarkers, CYP enzyme phenotypes, or star allele interpretation.
Comprehensive drug safety review integrating FDA labels, FAERS adverse event reports, disproportionality analysis, pharmacogenomics, clinical trials, and literature. Use for regulatory assessments, post-market surveillance, drug safety reviews, adverse event investigation, and pharmacovigilance.
Analyze drug safety signals from FDA adverse event reports, label warnings, and pharmacogenomic data. Calculates disproportionality measures (PRR, ROR), identifies serious adverse events, assesses pharmacogenomic risk variants. Use when asked about drug safety, adverse events, post-market surveillance, or risk-benefit assessment.
Comprehensive patient stratification for precision medicine by integrating genomic, clinical, and therapeutic data. Given a disease/condition, genomic data (germline variants, somatic mutations, expression), and optional clinical parameters, performs multi-phase analysis across 9 phases covering disease disambiguation, genetic risk assessment, disease-specific molecular stratification, pharmacogenomic profiling, comorbidity/DDI risk, pathway analysis, clinical evidence and guideline mapping, clinical trial matching, and integrated outcome prediction. Generates a quantitative Precision Medicine Risk Score (0-100) with risk tier assignment (Low/Intermediate/High/Very High), treatment algorithm (1st/2nd/3rd line), pharmacogenomic guidance, clinical trial matches, and monitoring plan. Use when clinicians ask about patient risk stratification, treatment selection, prognosis prediction, or personalized therapeutic strategy across cancer, metabolic, cardiovascular, neurological, or rare diseases.
Drug mechanism of action investigation -- systematic strategy to trace a drug from its primary target through pathways to clinical outcomes, identify off-target effects, and combine regulatory labels with literature evidence for a complete mechanism picture.